Hypoallergenic Vaccine may Ease Birch Pollen Allergies


Vienna - A hypoallergenic vaccine derived from genetically engineered birch pollen can reduce patients' allergic response to the pollen, according to Austrian researchers. A research team around Rudolf Valenta engineered the main birch pollen antigen, Bet v1, to be hypoallergenic and used it for vaccination of 124 patients over the course of one year. Individuals received the vaccine once before the peak of the birch pollen season, and were then screened throughout the year for IgE antibodies that cause allergic reactions by releasing inflammation mediators.
The immunologists found a 50% decrease in both IgE antibody and IgE memory cells together with a significant improvement of symptoms and increased levels of so-called IgG antibodies. They also found that the IgG level and the improvement of symptoms were dose-dependent. They speculate that the IgGs compete with the IgEs on the same antigen epitopes of the pollen, thereby providing a protective effect against rapid allergic reactions. The results of the clinical trial clearly indicate that the vaccine is capable of reducing the allergic response to future exposures to birch pollen. Valenta and his team also report fewer allergic side effects from the new vaccine. The authors indicate that hypoallergenic vaccines can be created with genetic engineering technology, or another recombinant DNA technology, to treat many common allergies known to affect more than 25% of the population in the industrialized world.



Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...



Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria


Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...



Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...



Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...



Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues